Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Drug PIC

MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China

Fineline Cube Sep 4, 2026
Company Deals PIC

Typewriter Therapeutics Raises USD 56 Million Series A to Advance TPRT RNA Gene Insertion Platform for In Vivo CAR-T and Liver Diseases

Fineline Cube Sep 4, 2026
Company Deals Drug PIC

Takeda and Belief BioMed End Xinjiuning Commercialization Partnership; Belief BioMed to Advance Gene Therapy Independently

Fineline Cube Sep 4, 2026
Company Deals Drug PIC

Keymed Biosciences Grants Aeira Exclusive Rights to Stapokibart Across 18 Southeast and Central Asia Markets, Securing High Double‑Digit Royalties

Fineline Cube Sep 3, 2026
Company Deals PIC

Medtronic Invests USD 700 Million in Cornerstone Robotics, Wins Distribution Rights for Sentire Endoscopic Surgical Robot Outside the U.S.

Fineline Cube Sep 3, 2026
Company Drug PIC

MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China

Fineline Cube Sep 4, 2026
Company Drug PIC

MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China

Fineline Cube Sep 4, 2026
Policy / Regulatory

China’s 2026 NHSA Drug Negotiations Open Sept 5 with Parallel Commercial Insurance Innovative Drug Catalog Talks

Fineline Cube Sep 4, 2026
Company Deals

Fosun Pharma to Acquire Full Stake in Fosun Kite Biotechnology for USD 27 Million

Fineline Cube Sep 14, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has disclosed plans to acquire...

Company Drug

Jiangsu Hengrui’s HER2-Targeted ADC SHR-A1811 Receives Priority Review from China’s NMPA

Fineline Cube Sep 14, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...

Company Deals Medical Device

Hangzhou-Based Ophthalmic Device Maker MDCO Secures RMB 200 Million in Series B Funding

Fineline Cube Sep 14, 2024

MDCO, an ophthalmic medical device company headquartered in Hangzhou, has reportedly secured nearly RMB 200...

Company Deals

Beijing Wantai Biological and Fujian Provincial CDC Collaborate on Vaccine Development and Public Health Initiatives

Fineline Cube Sep 14, 2024

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392), a leading biopharmaceutical company based in...

Company Deals

MGI Tech and Haihe Laboratory Deepen Collaboration with Introduction of CycloneSEQ-WT02

Fineline Cube Sep 14, 2024

MGI Tech Co., Ltd, a prominent gene sequencing company based in China, has disclosed a...

Company Deals

MGI Tech and Sequanta Technologies Launch Advanced DCS Lab to Accelerate Omics Research

Fineline Cube Sep 14, 2024

MGI Tech Co., Ltd, a leading gene sequencing specialist based in China, has entered into...

Policy / Regulatory

China Boosts Public Health Subsidies and Targets Weight Management in 2024

Fineline Cube Sep 14, 2024

The National Health Commission, Ministry of Finance, National Administration of Traditional Chinese Medicine, and National...

Policy / Regulatory

China’s NHSA and MOF Issue Notices to Enhance Cross-Regional Medical Treatment Direct Settlement

Fineline Cube Sep 14, 2024

The National Healthcare Security Administration (NHSA) and the Ministry of Finance (MOF) have issued two...

Policy / Regulatory

CDE Launches CARE Plan to Streamline Rare Disease Drug Development

Fineline Cube Sep 14, 2024

The Center for Drug Evaluation has unveiled the ‘Pilot Work Plan for Patient-Centered Action for...

Company

Moderna Inc. Announces Cost-Cutting Measures and Pipeline Realignment

Fineline Cube Sep 13, 2024

Moderna Inc. (NASDAQ: MRNA), a leading mRNA technology company based in the U.S., has announced...

Company Deals

Sino Biological and BioGeometry Broaden Partnership to Advance AI-Driven Drug Discovery

Fineline Cube Sep 13, 2024

Sino Biological (SHE: 301047), a leading biotech company in China, and BioGeometry have announced an...

Company Drug

Johnson & Johnson Submits Second NDA for Nipocalimab to Treat Generalized Myasthenia Gravis

Fineline Cube Sep 13, 2024

Johnson & Johnson (NYSE: JNJ), a leading healthcare company based in the U.S., has reported...

Company Drug

Keymed Biosciences’ IL-4Rα mAb Stapokibart Receives NMPA Approval for Atopic Dermatitis Treatment

Fineline Cube Sep 13, 2024

Keymed Biosciences Inc. (HKG: 2162), a biopharmaceutical company based in China, has announced that the...

Company Policy / Regulatory

South Korea’s MFDS Aims to Slash Drug Approval Times with New Innovation Plan

Fineline Cube Sep 13, 2024

South Korea’s Ministry of Food and Drug Safety (MFDS) has unveiled an ambitious plan to...

Company Deals Digital

Alibaba Health Forges Strategic Partnerships with Viatris and Chinese Pharma Companies for Digital Health Expansion

Fineline Cube Sep 13, 2024

Alibaba Health Information Technology Ltd (HKG: 0241), the health industry arm of Chinese e-commerce giant...

Company Deals

Shanghai Bao Pharmaceutical and Subsidiary Secure Commercialization Rights Deal for SJ02 with Organon China

Fineline Cube Sep 13, 2024

Shanghai Bao Pharmaceutical, a Chinese pharmaceutical company, along with its wholly-owned subsidiary Suzhou Centergene Pharmaceuticals,...

Company Deals

ChemPartner Pharmatech Enters Strategic Partnership with Malaysian Entities to Develop Innovative Drugs

Fineline Cube Sep 13, 2024

ChemPartner Pharmatech Co., Ltd (SHE: 300149), a leading pharmaceutical company based in China, has joined...

Company Deals

Nona Biosciences and Umoja Biopharma Join Forces to Develop In Vivo CAR-T Therapies

Fineline Cube Sep 13, 2024

Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a strategic...

Company Deals

Beijing’s MoleculeMind Secures Series A Funding to Accelerate AI Protein Design Innovations

Fineline Cube Sep 13, 2024

MoleculeMind, a Beijing-based AI protein design platform, has reportedly secured a Series A financing round,...

General/Other

Leadership Shuffle at China’s National Health Commission: Liu Jinfeng Steps in as Deputy Director

Fineline Cube Sep 13, 2024

The Ministry of Human Resources and Social Security has announced key leadership changes within the...

Posts pagination

1 … 348 349 350 … 716

Recent updates

  • MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China
  • China’s 2026 NHSA Drug Negotiations Open Sept 5 with Parallel Commercial Insurance Innovative Drug Catalog Talks
  • Trinomab’s Retavibart Wins NMPA Priority Approval as RSV Prevention Monoclonal Antibody Xinduotuo
  • Xuanzhu Biopharmaceutical Signs Thailand Commercial Agreement with Innobic and ZaoAn for Bireociclib
  • Betta’s Ensartinib Wins NMPA Approval for Third Indication as Adjuvant Therapy in ALK-Positive NSCLC
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug PIC

MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China

Policy / Regulatory

China’s 2026 NHSA Drug Negotiations Open Sept 5 with Parallel Commercial Insurance Innovative Drug Catalog Talks

Company Drug

Trinomab’s Retavibart Wins NMPA Priority Approval as RSV Prevention Monoclonal Antibody Xinduotuo

Company Deals

Xuanzhu Biopharmaceutical Signs Thailand Commercial Agreement with Innobic and ZaoAn for Bireociclib

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.